These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29382355)

  • 1. Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture.
    Cheng TT; Yu SF; Su FM; Chen YC; Su BY; Chiu WC; Hsu CY; Chen JF; Ko CH; Lai HM
    Arthritis Res Ther; 2018 Jan; 20(1):16. PubMed ID: 29382355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of High Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index With Low Bone Mineral Density in Rheumatoid Arthritis.
    Wysham KD; Shoback DM; Imboden JB; Katz PP
    Arthritis Care Res (Hoboken); 2018 Jul; 70(7):961-969. PubMed ID: 29106028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients.
    Sulaiman FN; Wong KK; Ahmad WAW; Ghazali WSW
    Medicine (Baltimore); 2019 Mar; 98(12):e14945. PubMed ID: 30896663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density, vitamin D receptor (VDR) gene polymorphisms, fracture risk assessment (FRAX), and trabecular bone score (TBS) in rheumatoid arthritis patients: connecting pieces of the puzzle.
    Senosi MR; Fathi HM; Baki NMA; Zaki O; Magdy AM; Gheita TA
    Clin Rheumatol; 2022 May; 41(5):1333-1342. PubMed ID: 35048212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study.
    Bøyesen P; Hoff M; Odegård S; Haugeberg G; Syversen SW; Gaarder PI; Okkenhaug C; Kvien TK
    Arthritis Res Ther; 2009; 11(4):R103. PubMed ID: 19570223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies Serum Level and 10-Year Risk of Fractures Evaluated by FRAX
    Sghiri R; Ben Hassine H; Ghozzi M; El Amri N; Baccouche K; Sarraj R; Shakoor Z; Almogren A; Bouajina E
    Open Access Rheumatol; 2024; 16():137-145. PubMed ID: 39045423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
    Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
    Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density lipoprotein in rheumatoid arthritis: emerging role in predicting inflammation level and osteoporosis occurrence.
    Zeng T; Tan L; Yu J; Wu Y
    Scand J Clin Lab Invest; 2020 Sep; 80(5):375-380. PubMed ID: 32279574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
    Berendsen MLT; van Maaren MC; Arts EEA; den Broeder AA; Popa CD; Fransen J
    J Rheumatol; 2017 Sep; 44(9):1325-1330. PubMed ID: 28668802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cyclic citrullinated peptide but not rheumatoid factor is associated with ultrasound-detected bone erosion among rheumatoid arthritis patients with at least moderate disease activity.
    Tan YK; Li H; Allen JC; Thumboo J
    Int J Rheum Dis; 2020 Oct; 23(10):1337-1343. PubMed ID: 33460311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis.
    Lee DM; Phillips R; Hagan EM; Chibnik LB; Costenbader KH; Schur PH
    Ann Rheum Dis; 2009 Feb; 68(2):201-8. PubMed ID: 18390910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis.
    Guler H; Turhanoglu AD; Ozer B; Ozer C; Balci A
    Scand J Rheumatol; 2008; 37(5):337-42. PubMed ID: 18609264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis.
    Shen R; Ren X; Jing R; Shen X; Chen J; Ju S; Yang C
    Lab Med; 2015; 46(3):226-9. PubMed ID: 26199263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Red Blood Cell Distribution Width and Inflammatory Factors for the Disease Activity in Rheumatoid Arthritis.
    Yunchun L; Yue W; Jun FZ; Qizhu S; Liumei D
    Clin Lab; 2016 Dec; 62(12):2327-2331. PubMed ID: 28164544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk factors for bone mineral density changes in patients with rheumatoid arthritis and fracture risk assessment].
    Wang Y; Hao YJ; Deng XR; Li GT; Geng Y; Zhao J; Zhou W; Zhang ZL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Oct; 47(5):781-6. PubMed ID: 26474615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co-existent bronchiectasis.
    Perry E; Eggleton P; De Soyza A; Hutchinson D; Kelly C
    Int J Rheum Dis; 2017 Dec; 20(12):2003-2011. PubMed ID: 26200759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort.
    Ahmad HA; Alemao E; Guo Z; Iannaccone CK; Frits ML; Weinblatt M; Shadick NA
    Adv Ther; 2018 Feb; 35(2):232-242. PubMed ID: 29368271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in Iranian patients with rheumatoid arthritis: evaluation of clinical value and association with disease activity.
    Shakiba Y; Koopah S; Jamshidi AR; Amirzargar AA; Massoud A; Kiani A; Nicknam MH; Nazari B; Nikbin B
    Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):147-56. PubMed ID: 24659118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort.
    Hafström I; Ajeganova S; Forslind K; Svensson B
    Arthritis Res Ther; 2019 Feb; 21(1):45. PubMed ID: 30717793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.